Elite Clinical Network Appoints Christopher Brennan as Chief Executive Officer
SCOTTSDALE, Ariz., June 02, 2025 ( GLOBE NEWSWIRE ) -- Elite Clinical Network ( ECN ) , a fully-integrated clinical research site network, has appointed Christopher ( "Chris" ) Brennan as its Chief Executive Officer.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apple Inc. - AAPL - Apple ( NASDAQ:AAPL )
NEW YORK, June 02, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Apple Inc. ( "Apple" or the "Company" ) AAPL. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Photronics, Inc. - PLAB - Photronics ( NASDAQ:PLAB )
NEW YORK, June 02, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Photronics, Inc. ( "Photronics" or the "Company" ) PLAB. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma - Zenas BioPharma ( NASDAQ:ZBIO )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Zenas To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT - Fulgent Genetics ( NASDAQ:FLGT )
NEW YORK, June 02, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ( "Fulgent" or the "Company" ) FLGT. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN - UroGen Pharma ( NASDAQ:URGN )
NEW YORK, June 02, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. ( "UroGen" or the "Company" ) URGN. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Disclosure of trading in own shares
Shares purchased following the program approved at the Shareholders' Meetings of May 29, 2024 and May 27, 2025. Total number of shares purchased according to trading venues: About Publicis Groupe - The Power of One Publicis Groupe [Euronext Paris FR0000130577, CAC 40] is a global leader in ...
Dave's Hot Chicken Entering Next Phase of Growth & Innovation with Roark
LOS ANGELES, June 02, 2025 ( GLOBE NEWSWIRE ) -- From a parking lot in 2017, to a global sensation which expects to end the year with more than 400 restaurants across the globe; Dave's Hot Chicken has chosen an investment from Roark, entering its next phase of growth and innovation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of New Fortress Energy Inc. - NFE - New Fortress Energy ( NASDAQ:NFE )
NEW YORK, June 02, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of New Fortress Energy Inc. ( "New Fortress" or the "Company" ) NFE. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT - Rocket Pharmaceuticals ( NASDAQ:RCKT )
NEW YORK, June 02, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. ( "Rocket" or the "Company" ) RCKT. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
